Longevity.Technology UNLOCKED

Find Nina Patrick here: https://qrco.de/bgXpKn----------Sponsor: GlycanAge Inflammaging drives CVD, metabolic disorders, and accelerated aging, but clinicians still lack reliable tools to measure, intervene, and track it in practice. GlycanAge brings together leading experts to close that gap with practical frameworks for assessing immune aging in real-world clinical settings.Register via the link below and join the one-day event to learn how to measure immune aging and apply it to preventive and longevity care.Date: June 20 2026 | Location: Hotel Dubrovnik Palace, CroatiaLink: https://glycanage.com/inflammaging-in-clinical-practice----------Guests: Nikolina LaucCEO & Co-Founder of GlycanAgeLinkedIn: https://www.linkedin.com/in/nikolinalauc/Website: https://glycanage.com/----------What if glycans—the neglected sugars on immune proteins—reveal inflammation and biological age more accurately than DNA methylation or CRP?Phil Newman and Dr. Nina Patrick sit down with Nikolina Lauc, CEO and co-founder of GlycanAge, to explore how these biomarkers integrate genetics, epigenetics, and environment for superior aging insights.Together they explain glycan shifts predicting cardiovascular events better than standard markers, with 300,000+ samples showing changes up to 10 years before diabetes. From perimenopause accelerating biological age by nine years (or decades in months for some) to moderate exercise yielding 10 years younger profiles versus pros matching sedentary inflammation, these reveal immune-driven aging realities. Contrasting epigenetic clocks' 10% variability (five-year swings same-day), glycans stay stable within one year.They also discuss hormone replacement reversing effects, fasting dropping profiles in days despite 21-day half-life, overtraining myths, and psychology like PTSD adding 15 years immune age—pushing immune resilience scores over raw age.In this episode, you’ll learn:Glycans predict CV risk/mortality across 350+ papers, outperforming CRPPerimenopause doubles aging rate; estrogen reverses 9-year spikeOver-exercisers match sedentary inflammation; moderates gain 10 yearsFasting alters glycans in days vs 21-day half-lifeStress/divorce adds decades; PTSD shortens expectancy 15-20 yearsGlycans enable modifiable risk scores for hospitals like NorthwesternIf you want to understand why inflammation may be the true driver of aging, this episode connects large-scale glycan data with real-world clinical implications for prevention and longevity.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Find Nina Patrick here: https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine epigenetic consolidation, SuperAge Games, Endless funding, Genflow gene therapy partnership, knee implants, and longevity business models.Infinite Epigenetics acquired Tally Health, gaining its cheek swab biological age test and supplement recommendations. Largest epigenetic datasets could edge personalized medicine.SuperAge announced the SuperAge Games in New York this November, a healthspan-focused competition like CrossFit testing endurance, strength, balance, cognition, and social capacity via biomarkers. It reframes athleticism for durability over intensity, celebrating competitors at 50-70. Contrasts enhanced games by prioritizing sustained resilience.Endlyz closed Seed 2 funding for root-cause neurodegeneration targeting beyond plaques or inflammation. Aims for early causal interventions differing from symptom treatments. Needs specific mechanisms and biomarkers for credibility amid neuro translation challenges. Genflow Biosciences partnered with Acuitas Therapeutics on SIRT6 mRNA from centenarians for DNA repair, using proven lipid nanoparticles fully funded by Acuitas. De-risks delivery for preclinical tests in dogs and beyond and signals promise in aging gene therapy.Smith+Nephew's FDA-approved AGILI-C knee implant showed superior 5-year pain reduction and mobility in mild-moderate osteoarthritis. Targets treatment gap patients, with CPT reimbursement in 2027. Companies race longevity-ready models profiting from healthspan in healthcare to workplaces via screenings and benefits. Hard metrics on absenteeism excite employers at Longevity Show, and flips sickcare threats to assets.----------Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------News & References:Infinite Epigenetics acquires Tally Health → https://longevity.technology/news/infinite-epigenetics-acquires-tally-health/Super Age debuts world’s first longevity fitness games → https://longevity.technology/news/super-age-debuts-worlds-first-longevity-fitness-games/Endlyz raises Seed 2 financing, leans into root-cause neuroscience → https://longevity.technology/news/endlyz-raises-seed-2-financing-leans-into-root-cause-neuroscience/Genflow teams with Acuitas on gene delivery in fully-funded deal → https://longevity.technology/news/genflow-teams-with-acuitas-on-gene-delivery-in-fully-funded-deal/Knee implant outperforms standard care at 5 years → https://longevity.technology/news/knee-implant-outperforms-standard-care-at-5-years/Inside the race to build longevity-ready business models → https://longevity.technology/news/inside-the-race-to-build-longevity-ready-business-models/

Find Nina Patrick here: https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------Guests:JJ VirginFounder of Health Business Growth Collective and Well Beyond 40Instagram: https://www.instagram.com/jj.virgin/Website: https://jjvirgin.com/----------What if the key to living longer wasn’t a pill, but making your body stronger?Phil Newman and Dr. Nina Patrick sit down with JJ Virgin, triple board-certified nutrition expert, fitness hall of famer, and founder of the Health Business Growth Collective, to explore how muscle drives strength, resilience, and decades of high performance. According to JJ, muscle quietly slips away after 30. Protein synthesis drops 30% per decade, hitting women earliest and hardest as perimenopause estrogen fades against their lower starting mass. Grip strength reveals the truth first, signaling all-cause mortality risk—the weakest quartile faces the steepest odds—even as 50% of normal-weight adults harbor sarcopenic obesity, blending frailty with hidden fat that rushes aging.JJ cuts through the noise. Grip dynamometer tests deliver the simplest proxy: squeeze for "great" versus your age group, with under 10% hand asymmetry. She flips GLP-1s on their head—build muscle first with protein matched to ideal weight and fat-free mass tracking, then cut calories. Beginners start her 2x2x2: two days weekly, two moves per body part, two sets to near-failure. Neural gains arrive before the mirror notices.In this episode, you’ll learn:Grip strength predicts mortality. Test 3x per side; track gains as neural adaptations lead hypertrophy by 6-8 weeks.Build muscle first. GLP-1s expose weak diets, risking 40% muscle loss on calorie cuts without resistance training.- Women lose fast-twitch fibers quickest. Challenge with 6-12 reps near failure to rebuild power.Resting metabolic rate climbs 7-10 calories per pound of muscle; protein-first meals spike thermic effect 25%.Start simple: pushups (wall to toes), squats to chair (30-sec power test), rows. Progress from bodyweight to loads.40 years of clinical insights deliver actionable tests and programming against gravity's pull.If you want to understand how muscle powers healthspan against gravity-fueled decline, this episode connects 40 years of clinical insights with actionable tests and programming for powerful aging.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Find Nina Patrick here: https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine energy span as a fatigue biomarker, GSK's $950M 35 Pharma acquisition, January AI's Medicare app entry, OsteoBoost's $8M funding, Seragon's SRN-901 33% mouse lifespan boost, and skin longevity advances.Energy span proposes viewing fatigue as an early mitochondrial decline signal before chronic disease. Advances in wearable technology and continuous monitoring are making it possible to track proxies of energy regulation – heart rate variability as a marker of autonomic balance, glucose dynamics as a reflection of metabolic stability, sleep architecture as a proxy for recovery.GSK acquired 35Pharma for $950M, gaining a pulmonary hypertension candidate affecting lung arteries. Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF).January AI joined Medicare's app library for 69M users, using food photos and AI to predict glucose responses. It lowers barriers for metabolic coaching but needs integration and targeting for adoption.OsteoBoost raised $8M for a vibration wearable mimicking bone-loading to combat osteoporosis in 200M worldwide. It offers non-drug options amid bisphosphonate trade-offs, with mixed prior studies on dose.Seragon's oral SRN-901 extended late-life mouse lifespan 33%, cut frailty 70%, tumors 30% via mitophagy and NAD support, outperforming rapamycin.Epicutis' TCP serum improved skin appearance 77% in 8-week trial versus placebo, signaling cellular modulation in aesthetics.----------Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------News & References:GSK acquires 35Pharma in $950m deal, advancing PH drug → https://longevity.technology/news/gsk-acquires-35pharma-in-950m-deal-advancing-ph-drug/Energy Span reframes fatigue as early warning → https://longevity.technology/news/energy-span-reframes-fatigue-as-early-warning/Osteoboost raises $8m to scale bone wearable → https://longevity.technology/news/osteoboost-raises-8m-to-scale-bone-wearable/January AI enters Medicare App Library, reaches 69m+ patients → https://longevity.technology/news/january-ai-enters-medicare-app-library-reaches-69m-patients/Seragon study shows SRN-901 extends median lifespan in mice → https://longevity.technology/news/seragon-study-shows-srn-901-extends-median-lifespan-in-mice/Epicutis clinical study shows 77% improvement in skin appearance → https://longevity.technology/news/epicutis-clinical-study-shows-77-improvement-in-skin-appearance/

Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED-----Guest:Tim GrayFounder, Health Optimization SummitWebsite: https://healthoptimization.com/Instagram: https://www.instagram.com/timbiohacker/-----What if biohacking is not about doing more, but about doing less, better?Phil Newman and Dr. Nina Patrick sit down with Tim Gray, founder of the Health Optimization Summit and one of the most influential figures in the biohacking movement, to explore how the space has evolved from niche experimentation to mainstream health optimization. From supplements and wearables to nervous system regulation and community-driven health, Tim shares what actually moves the needle and what does not.They discuss the shift from complex protocols to foundational health principles, why oversupplementation and excessive data can backfire, and how environment and lifestyle often outperform expensive technologies. The conversation also explores emerging trends including peptides, stem cells, microplastics, and the growing importance of nervous system regulation.The episode examines how large-scale personal data is shaping health insights, the balance between personal experimentation and clinical evidence, and why loneliness may be one of the most overlooked risks to longevity.In this episode, you will learn:How biohacking has evolved into health optimizationWhy simplifying your health routine often leads to better resultsThe risks of oversupplementation and over-reliance on dataHow environment influences the need for health technologiesThe role of peptides and stem cells in the future of medicineWhy nervous system regulation is becoming a central pillar of healthThe impact of community and relationships on longevityHow to think about personalization versus foundational health principlesIf you want to understand where the longevity and biohacking space is heading and how to focus on what actually works, this episode offers a grounded, experience-led perspective on optimizing health in a complex world. Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.-----Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore the $67B longevity market projection, Technogym’s Google partnership, Function Health’s acquisition, mitochondrial transplants, clinical education, and the rise of workforce healthspan.A new report projects the longevity and healthy aging market will reach $67B by 2035, spanning therapeutics, diagnostics, supplements, and lifestyle interventions. Growth signals mainstream adoption, but raises concerns around “longevity washing” and the need for stronger scientific validation.Technogym expands its partnership with Google Cloud to build AI-powered, personalized fitness and health coaching. Alongside moves from L’Oréal and wearables players, big tech and legacy brands are embedding longevity into everyday consumer platforms.Function Health acquires GetLabs to enable at-home blood draws, removing friction in biomarker testing. The move strengthens longitudinal health tracking, though success depends on pairing access with meaningful clinical guidance.Mitrix Bio reports early safety data on mitochondrial transplants, injecting lab-grown mitochondria to restore cellular energy. With only two participants and clinics already launching under “Right to Try,” the approach highlights tensions between innovation speed and clinical evidence.Longevity.Technology launches a clinical education marketplace, curating vetted training programs for clinicians, founders, and consumers. The platform aims to address fragmentation and raise standards across the rapidly evolving sector.Employers are shifting toward healthspan-focused benefits, prioritizing diagnostics, mental health, and preventative care over traditional perks. Workforce longevity strategies are emerging as a key lever for productivity, retention, and cost control.----------Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------News & References:Technogym & Google Cloud partnership → https://longevity.technology/news/technogym-and-google-cloud-expand-ai-fitness/Function Health acquires GetLabs → https://longevity.technology/news/function-acquires-getlabs-to-scale-at-home-testing/Mitrix Bio mitochondrial transplant trials → https://longevity.technology/news/mitrix-moves-mitochondria-into-the-clinic/Longevity.Technology education marketplace launch → https://longevity.technology/news/education-platform-targets-longevity-knowledge-gap/Workforce healthspan trends → https://longevity.technology/news/workers-rethink-benefits-healthspan-comes-first/

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED______________________Guests:Dr Terry WahlsPhysician and Author of The Wahls ProtocolWebsite: https://terrywahls.com/______________________What if autoimmune disease isn’t irreversible, but a reflection of deeper dysfunction at the cellular level?Phil Newman and Dr. Nina Patrick sit down with Dr. Terry Wahls, clinician, researcher, and author of The Wahls Protocol, to explore how diet, lifestyle, and cellular health can reshape outcomes in chronic disease. Diagnosed with progressive multiple sclerosis and confined to a wheelchair, Dr. Wahls applied a science-led, systems-based approach to restore her function, challenging conventional assumptions about what is possible in autoimmune conditions.They explore how mitochondria, the microbiome, and immune function interact to drive disease, and how targeted interventions across nutrition, movement, and lifestyle can improve resilience, energy, and overall health.The conversation covers nutrient density, gut health, fasting, fats, and behavioural change, connecting clinical science with practical application. It also examines the resistance faced by non-traditional approaches in medicine, the difficulty of funding complex lifestyle research, and why personalised, systems-level thinking may shape the future of healthcare.In this episode, you will learn:How Dr. Wahls went from wheelchair-bound to walking and cycling againThe role of mitochondria and cellular function in autoimmune diseaseHow diet, gut health, and the microbiome influence immunity and brain healthWhy ultra-processed foods drive inflammation and chronic diseaseThe importance of personalised nutrition and lifestyle interventionsHow to use “biosensors” to track what works for your bodyThe limitations of current microbiome testing and one-size-fits-all dietsIf you want to understand how science-backed lifestyle interventions can influence chronic disease, performance, and long-term health, this episode offers a clear and evidence-informed perspective on what is possible.Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED__________________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GeneRare funding, Noom's pharmacy buy, Anovis neuro combos, Life Biosciences reprogramming, wearable partnerships, and Peloton at Longevity Show.Generare raised $21.6M (€20M) Series A to scale microbial genome scanning for novel natural product molecules, identifying 200+ hits in 2025. Funds expand libraries from plants, fungi, marine sources and team to 50 for bioactive drug leads. AI optimizes hits despite supply/IP challenges, eyeing geroprotectors like rapamycin analogs.Noom acquired a 503A compounding pharmacy to dispense GLP-1s, peptides like sermorelin, NAD+ with behavioral coaching for healthy aging. Vertical integration pairs app data with pharma access to scale longevity interventions. Success needs strong clinical governance over revenue incentives.Annovis advances buntanetap, oral molecule from Calabar bean "execution poison," reducing amyloid beta, tau, alpha-synuclein translation in phase 3 Alzheimer's and Parkinson's trials. Combos with sildenafil boost cerebral blood flow, NO-cGMP as vascular support. Life Biosciences landed $80M Series D to push ER-100 partial epigenetic "cell reset" therapy into phase 1 for optic neuropathies like glaucoma. Targets retinal ganglion cell rejuvenation as beachhead for organ-specific proofs toward systemic aging reversal. Measurable vision outcomes validate reprogramming.Agentis partners Ultrahuman integrating CGM/HRV into Longevity Quotient platforms; Well Health ties AliveCor for AI-ECG AFib detection in Canada. Wearables enable dynamic monitoring beyond snapshots for arrhythmias, metabolic drift. Demand proven clinical outcomes over data noise.Peloton named official movement partner for Longevity Show 2026 (June 26-27, London) with rooftop workouts, 5K runs, rave featuring Leanne Hainesby. Anchors exercise as healthspan core alongside biomarkers, bridging fitness-longevity audiences. Preview April 19 Covent Garden.______________________News & References:Generare bags $21.6m for nature-derived drug leads → https://longevity.technology/news/generare-bags-21-6m-for-nature-derived-drug-leads/ Noom buys pharmacy to push into healthy aging → https://longevity.technology/news/noom-buys-pharmacy-to-push-into-healthy-aging/Annovis traces buntanetap’s road to Alzheimer’s → https://longevity.technology/news/annovis-traces-buntanetaps-road-to-alzheimers/Life Biosciences lands $80m to push cell reset therapy → https://longevity.technology/news/life-biosciences-lands-80m-to-push-cell-reset-therapy/Agentis, Ultrahuman tie wearables to longevity care → https://longevity.technology/news/agentis-ultrahuman-tie-wearables-to-longevity-care/Peloton named Movement Partner for The Longevity Show 2026 → https://longevity.technology/news/peloton-named-movement-partner-for-the-longevity-show-2026/______________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED______________________Guests:Ashley ZehnderCEO, Fauna BioLinkedin: www.linkedin.com/in/ashley-zehnder-31950827/Website: faunabio.com/Daniel OliverCo-Founder & CEO, Rejuvenate BioLinkedin: www.linkedin.com/in/danielcoliver/Website: rejuvenatebio.com/______________________What if the animal kingdom holds the key to improving human healthspan and performance?Phil Newman and Dr. Nina Patrick sit down with Ashley Zehnder, CEO of Fauna Bio, and Daniel Oliver, CEO of Rejuvenate Bio, to explore how insights from hibernating animals, long-lived species, and regenerative models are shaping next-generation longevity therapies. From metabolic adaptations and ketone utilization to epigenetic reprogramming, they reveal how studying other species can guide interventions for human health, recovery, and overall wellness.Together they explain how species that naturally resist disease, survive extreme conditions, or regenerate tissues provide a roadmap for interventions in humans. From hibernating mammals that switch to ketone-based metabolism to long-lived rodents showing epigenetic resilience, these insights are shaping therapies that target recovery, metabolism, and overall wellness.They also discuss how these discoveries could inform practical strategies for human health, from personalized nutrition and exercise to novel drug targets that mimic nature’s resilience.In this episode, you’ll learn:How gene therapies in animals improve endurance, recovery, frailty, and lifespan- What hibernating animals and high-performance species teach about metabolism and resilienceHow AI and comparative genomics accelerate drug discovery and improve translational successCommon misconceptions about translating animal biology to human healthFuture priorities in longevity research, including regenerative biology and disease resistanceIf you want to understand how comparative biology and cutting-edge therapies are unlocking new pathways to enhance human healthspan, this episode connects science from the animal kingdom with actionable insights for human longevity.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED______________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor. Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.______________________News & References:PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/ Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/ Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/ Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/ Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/ Private clinics face longevity learning curve → https://longevity.technology/news/private-clinics-face-longevity-learning-curve/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: ⁠fatty15.com/UNLOCKED______________________Guests: Dr. Aubrey de GreyPresident and CSO at LEV FoundationLinkedin: www.linkedin.com/in/aubrey-de-grey-24260b/Website: www.levf.org/______________________What if aging is not inevitable… but something we can actively manage?Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.In this episode, you’ll learn:How intrinsic capacity and resilience can measure functional aging earlier than traditional methodsWhy preventative medicines face societal and regulatory barriersHow high-profile advocates and clinics are shaping public acceptance of longevity therapiesEthical and practical considerations for equitable access worldwideWhere Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.______________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Affiliate link: https://www.getstride.com/unlocked/____________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore cutting-edge developments in longevity, from hibernating animals inspiring obesity treatments to AI-driven industry insights and the world’s first Parkinson’s test kit. FaunaBio identified a metabolic target from hibernating mammals that could preserve muscle during weight loss. The California-based company said the achievement triggers an undisclosed milestone payment as part of a multi-year agreement signed with Lilly in 2023, which could be worth up to $494 million. This will advance this first-in-class approach, signaling serious pharma conviction in extreme-animal-inspired drug discovery. Longevity.Technology developed DLT (Decoding Longevity Trends), a three-stage AI system to gather, fact-check, and synthesize complex longevity data. DLT tracks over 700 longevity and age-related disease biotechs in paid-beta; the broader datasets (800+ wider ecosystem companies and 300+ longevity clinics) will be released in 2H26.The MODAG's PD Detect kit measures alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, moving Parkinson’s diagnosis from observation to evidence. Early detection can help enroll patients at stages where disease-modifying drugs have the best chance of success. The Senotherapeutics Biomarker Consortium (SBC) aims to standardize cellular senescence measurement in humans to support regulators, clinicians, and drug development. Framed as a precompetitive collaboration, it brings together academia, industry and regulators to do something less glamorous than drug discovery, but arguably more necessary – to agree on how senescence should be measured, validated and ultimately trusted in the clinic.The experimental pill Enlicitide lowered LDL cholesterol by 57% in a phase three trial of 2,909 patients with cardiovascular risk. Daily oral dosing could finally improve compliance compared with injectable PCSK9 inhibitors, potentially reducing cardiovascular events at a population level.Cardiovascular disease and cancer (particularly colon cancer) and “external causes” remain top mortality risks. These conditions are leading causes of death for Gen X and Millennials, highlighting the urgent need for early detection and preventive health strategies.____________________News & References:Fauna Bio hits key milestone in Lilly obesity drug collab → https://longevity.technology/news/fauna-bio-hits-key-milestone-in-lilly-obesity-drug-collab/Longevity.Technology has quietly become an AI company → https://longevity.technology/news/longevity-technology-has-quietly-become-an-ai-company/MODAG brings world’s first Parkinson’s test to market → https://longevity.technology/news/modag-brings-worlds-first-parkinsons-test-to-market/Senescence consortium targets biomarker gap → https://longevity.technology/news/senescence-consortium-targets-biomarker-gap/Experimental pill cuts ‘bad cholesterol’ by up to 60% → https://longevity.technology/news/experimental-pill-cuts-bad-cholesterol-by-up-to-60/Longevity wake-up call for younger generations → https://longevity.technology/news/longevity-wake-up-call-for-younger-generations/____________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:Dr Lara Briden Naturopathic doctor and Bestselling AuthorInstagram: www.instagram.com/larabriden/Website: www.larabriden.com/Dr Molly MaloofEducator, Author, and Founder of AdamoInstagram: www.instagram.com/drmolly.co/?hl=enWebsite: https://drmolly.co/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: www.getstride.com/unlocked/______________________What if the key to female longevity has been hiding in plain sight?In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.In this episode, you’ll learn:Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.How evolutionary biology explains menopause as a “superpower” for human survival.Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals. Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.______________________News & References:Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:Dr. Dave Rabin MD, PhDFounder of Apollo NeuroLinkedin: www.linkedin.com/in/drdavemdphd/Website: https://apolloneuro.com/Dr Pedram ShojaiFounder of The Urban MonkInstagram:www.instagram.com/drpedramshojai/Website: https://theurbanmonk.com/___________________Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: www.getstride.com/unlocked/___________________What if stress isn’t something to eliminate… but something to train?Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.In this episode, you’ll learn:How chronic stress alters brain function, sleep, and long-term healthWhy recovery should be scheduled like performanceHow breathwork and somatic practices activate safety pathwaysThe role of circadian rhythm in resilience and cognition Where wearable technology helps and where it doesn’tIf you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.___________________Hosts: Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic longevity platforms.A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies._____________________News & References:GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/_____________________Hosts:Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠

Guests: Dr James GoolnikFounder of Optimal Dental HealthInstagram: www.instagram.com/jamesgoolnik/?hl=enWebsite: www.optimaldentalhealth.co.uk/Dr Aoife StackCo-founder of Airway SchoolInstagram: www.instagram.com/doctor_aoife/?hl=enWebsite: www.airwayschool.co.uk______________________What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.In this episode, you’ll learn:Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain healthHow simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and postureThe role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilienceStrategies for sustainable sugar reduction and habit stacking to protect oral and systemic healthIf you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health screening, ovarian longevity research, and nanotech biosensing, this episode connects science, innovation, and real-world impact.The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.Mainstream pharma is also advancing longevity research. Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity._____________________News & References:ARPA-H pours millions into healthspan-focused human trials → https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trialsWearable startup Temple secures $54m for brain monitoring → https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/YOU(th) lands funding for smartphone-based preventive health screening → https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/Richter sharpens ovarian aging focus following Celmatix asset deal → https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/How billionaires die → https://longevity.technology/news/how-billionaires-die/Nanotech startup lands funding for continuous biosensing platform → https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/_____________________Hosts:Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn

Guests:Allen Law Founder and CEO of MORROWLinkedin:https://www.linkedin.com/in/allenlawphg/Website:https://morrow.health/Dr William TanClinical Governance Officer of MORROWLinkedin: https://www.linkedin.com/in/dr-william-tan-05438649/Website: https://morrow.health/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link:https://www.getstride.com/unlocked/______________________What if longevity wasn’t a treatment… but a system you live inside every day?In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.In this episode, you’ll learn:Why preventive healthcare often fails despite widespread testingHow Morrow connects diagnostics directly to daily lifestyle interventionsThe role of AI in turning health data into consistent habit changeWhy community and purpose influence long term health outcomesHow accessibility could reshape the longevity clinic industryWhat Singapore’s healthcare model reveals about future global systemsWhy small consistent habits outperform short term health resolutionsIf you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials, wearable lactate sensors, and AI models targeting aging-linked inflammation, this episode connects science, innovation, and real-world impact.Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia. Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease. In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.______________________News & References:Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Alexander Zhavoronkov Founder, CEO and CBO at Insilico MedicineLinkedin: www.linkedin.com/in/zhavoronkov/Website: https://insilico.com/______________________What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.In this episode, you’ll learn:Why early diagnostics may currently be the most reliable longevity strategy.How AI can design drug candidates in months instead of years.- Why most longevity drugs succeed in animals but fail to prove benefits in humans.How disease focused therapeutics could become future aging interventions.What GLP-1 drugs reveal about the future of longevity medicine.The real role of clinical trials in validating AI generated therapies.How next generation technologies like brain computer interfaces could extend healthy lifespan.If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable. ______________________News & References:What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Christian DrapeauFounder + Chief Science Officer of STEMREGENInstagram: https://www.instagram.com/stemcellchristian/Website: https://www.stemregen.co/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________What if your body had a repair system that could predict and prevent age-related disease?Phil Newman and Dr. Nina Patrick sit down with Christian Drapeau, a researcher and expert in stem cells and regenerative biology. Christian explains how stem cells act as the body’s natural repair system, why measuring them could become a key biomarker for health, and how lifestyle factors, diet, and specific plant compounds can optimize their activity.They explore the science behind stem cell release, how exercise, fasting, meditation, sauna, and cold exposure support regeneration, and the emerging technologies helping stem cells reach their full potential. Christian also discusses targeted applications for heart repair, joint health, and other tissues, as well as the future of accessible stem cell measurement.This conversation highlights that supporting longevity goes beyond lifestyle hacks or clinical treatments. Christian’s research shows that understanding stem cell biology, preparing the body’s “terrain” for repair, and aligning interventions with evidence-based science are all critical for extending healthspan and improving long-term quality of life.In this episode, you’ll learn:Why stem cells are the cornerstone of the body’s repair systemHow measuring stem cells could predict age-related disease and track healthLifestyle and diet strategies to naturally boost stem cell releaseHow technology like PMF, sauna, and cold exposure works with stem cellsTargeted stem cell applications for heart, joints, and tissue repair careIf you care about protecting your long-term health and want to understand how science, technology, and clinical strategies intersect to shape the future of healthspan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies, interventions, and technologies helping us understand and harness the body’s natural repair systems.______________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.______________________News & References:Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevityDanish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:Carolyn Ringel, JD, MBEConsultant and Instructor for Harvard Medical School Center for BioethicsLinkedIn: https://www.linkedin.com/in/carolyn-baker-ringel-35378431/David Barzilai, MD, PhD, MBA, MS, DipABLMFounder and CEO of Barzilai Longevity ConsultingLinkedIn: https://www.linkedin.com/in/agingdoc/Website: https://www.barzilaiconsulting.com/david________________Longevity ethics? What if extending healthspan required rethinking not just medicine, but society itself?Phil Newman and Dr. Nina Patrick sit down with Carolyn Ringel, a bioethicist at Harvard Medical School, and Dr. David Barzilai, a longevity medicine physician. They explore how aging research and geroscience can address urgent health issues like heart disease, diabetes, cancer, and dementia, while highlighting the ethical responsibilities of science and medicine.Carolyn emphasizes that studying aging is not an either-or with addressing current health crises; by understanding aging, we can better prevent and treat age-related diseases. She also explores how healthcare funding, housing, and social infrastructure can be designed to support longer, healthier lives, creating a society where longevity benefits everyone.David explains the importance of trusted patient-doctor relationships, scientific literacy, and emerging interventions like aging biomarkers, cellular reprogramming, and regenerative medicine. He highlights the potential of integrated, systems-based approaches and AI-driven research to accelerate the development of safe, effective longevity strategies.This conversation highlights that longevity is not just about supplements, exercise, or clinical interventions. Ethical frameworks, societal design, and evidence-based medicine all play a crucial role in extending healthspan and improving quality of life.In this episode, you’ll learn:How geroscience can prevent multiple age-related diseases simultaneouslyThe ethical considerations of patient empowerment and longevity interventionsHow societal infrastructure and healthcare funding can support longer, healthier livesThe role of biomarkers and AI in safe, effective longevity strategiesThe future of integrated, evidence-based, and ethical longevity careIf you care about protecting your long-term health and want to understand how ethics, policy, and science intersect to shape the future of healthspan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies, policies, and strategies ________________Connect with our hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠ Dr. Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity, from new insights into genetic influence on lifespan to reproductive longevity, exosome therapeutics, AI health platforms, epigenetic reprogramming, and psychedelics for cognitive resilience.New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.______________________News & References:Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest:Dr Hany DemianCEO, Praesentia Healthcare Website: https://drdemian.com/ LinkedIn: https://www.linkedin.com/in/hany-demian-md-5b79b659/_________________What if chronic pain wasn’t just something to manage, but a key signal of deeper biological stress? And what if regenerative medicine could play a role in protecting long-term health and function?In conversation with Phil Newman and Dr. Nina Patrick, Dr. Hany Demian explores how regenerative medicine and peptide-based therapies are being used to support recovery, mobility, and healthy aging. He explains how chronic pain is often linked to inflammation, metabolic dysfunction, and impaired tissue repair rather than isolated injury.Dr. Demian highlights how tools such as PRP, peptides, cell-based therapies, and AI-assisted diagnostics can optimize repair, monitor progress, and guide personalized treatment plans, all while maintaining ethical, patient-centered care. The conversation shows how individualized protocols, informed by AI and clinical oversight, can improve outcomes without relying on one-size-fits-all solutions.This discussion reinforces that longevity is not only about supplements or exercise. Addressing pain, inflammation, and tissue health with precision medicine is a critical but often overlooked component of healthspan.In this episode, you’ll learn:How chronic pain affects long-term healthWhy regenerative approaches focus on repair, not symptom maskingThe role of AI and personalized treatment planningHow ethical oversight matters in regenerative careWhat the future of regenerative medicine may holdIf you care about protecting mobility, reducing chronic pain, and supporting long-term healthspan, this is a conversation you won’t want to miss.Subscribe for weekly episodes exploring longevity science, healthspan optimization, and emerging regenerative therapies.________________Connect with our hosts:Phil Newman: ⁠https://qrco.de/bgXpNY Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn

The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.____________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from epigenetic reprogramming and non-invasive brain therapies to AI-driven diagnostics.Elon Musk, speaking at Davos, suggested that aging is “very solvable,” framing it as an engineering challenge and emphasizing the growing mainstream awareness that biology can be engineered to extend healthspan.New research shows that sound stimulation at 40 Hz may help the brain clear toxic proteins linked to Alzheimer’s disease, offering a non-invasive, scalable approach to cognitive health if validated in humans.SimonMed launches longevity-focused MRI programs across the US, combining AI-enabled whole-body scans with lab testing and biomarkers to identify risks before symptoms arise.Researchers develop tiny wireless brain implants that can cross the blood-brain barrier without surgery, potentially transforming interventions for neurological aging and disease.Longevity has moved from lab benches to beauty counters, but as the category scales, experts warn that science-lite marketing could hollow it out.India’s Sun Pharma readies to launch generic semaglutide for weight management after patent expiry in 2026.____________________News & References:Elon Musk suggests aging is ‘very solvable’ → https://longevity.technology/news/elon-musk-suggests-aging-is-very-solvable/Non‑invasive sound therapy shows promise for Alzheimer’s → https://longevity.technology/news/non-invasive-sound-therapy-shows-promise-for-alzheimers/SimonMed launches longevity‑focused MRI program → https://longevity.technology/news/simonmed-launches-longevity-focused-mri-program/Sun Pharma gets approval for Wegovy-style weight loss shot → https://longevity.technology/news/sun-pharma-gets-approval-for-wegovy-style-weight-loss-shot/Brain implants may soon work without surgery → https://longevity.technology/news/brain-implants-may-soon-work-without-surgery/As longevity beauty grows, fears of ‘longevity washing’ rise → https://longevity.technology/news/as-longevity-beauty-grows-fears-of-longevity-washing-rise/____________________Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

Guest: Dr Miguel StanleyFounder and clinical director of White ClinicWebsite: https://miguelstanley.com/Instagram: https://www.instagram.com/drmiguelstanley/?hl=enSponsor: The Longevity Show Website: https://longevityshow.com/ The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.____________________What if your dentist could do more than just fix teeth? What if oral health became a key driver of long-term wellness and longevity?Phil Newman and Dr. Nina Patrick sit down with Miguel Stanley, a pioneer in longevity-focused dentistry. He explains how outdated dental work can create subclinical infections that contribute to systemic inflammation, impacting over 22 chronic diseases. Using CBCT imaging, strategic sequencing, and AI-assisted diagnostics, Miguel shows how modern dentistry can protect both healthspan and quality of life.He introduces revision dentistry, removing or updating old dental work that no longer supports health, and emphasizes ethical, patient-centered care. Patients who are informed and supported by AI can make smarter choices, while dentists can deliver more precise, preventive, and personalized care.This conversation highlights that longevity is not just about diet, supplements, or exercise. Oral health is a hidden lever for systemic wellness. With advanced diagnostics, treatment planning, and patient empowerment, dentistry can play a vital role in extending healthspan.In this episode, you’ll learn:How subclinical oral inflammation affects systemic healthWhy revision dentistry is critical for longevityThe role of AI in accurate diagnostics and patient empowermentHow sequencing dental treatments can optimize outcomesThe future of preventive, longevity-focused dentistryIf you care about protecting your long-term health and want to understand how oral care impacts your entire body, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies and strategies shaping the future of preventive, longevity-focused dentistry.____________________Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from brain-computer interfaces and AI-driven diagnostics to spaceflight epigenetics and longevity event updates.Merge Labs, Sam Altman’s BCI startup, launches with funding from OpenAI, exploring next-generation neural interfaces that could merge human cognition with AI.Lumati introduces an at-home saliva microplastics test, giving individuals a practical way to track environmental exposure and its potential health impacts.Spaceflight research reveals dynamic DNA methylation changes in astronauts on the Axiom 2 mission, offering fast insights into biological aging and epigenetic plasticity.The Houstonian Hotel, Club & Spa has appointed Fountain Life as its exclusive partner for longevity and preventive health services.The Longevity Show 2026 gears up with NAD Clinic as an official Innovator Partner, plus new speakers announced, highlighting the convergence of longevity clinics, wellness, and technology.Investment momentum continues to accelerate across longevity ventures, reflecting growing interest in diagnostics, neurotech, and preventive health innovations.__________News & References:Sam Altman’s BCI startup Merge Labs launches with funding from OpenAI → https://longevity.technology/news/sam-altmans-bci-startup-merge-labs-launches-with-funding-from-openai/Lumati launches at-home saliva microplastics test → https://longevity.technology/news/lumati-launches-at-home-saliva-microplastics-test/NADclinic named Innovator Partner for The Longevity Show 2026 → https://longevity.technology/news/nadclinic-named-innovator-partner-for-the-longevity-show-2026/Longevity Show reveals second wave of speakers → https://longevity.technology/news/longevity-show-reveals-second-wave-of-speakers/SciNeuro and Novartis ink $1.7b deal for new Alzheimer’s treatment →https://longevity.technology/news/scineuro-and-novartis-ink-1-7b-deal-for-new-alzheimers-treatment/Fountain Life named exclusive longevity partner of Houstonian hotel and spa → https://longevity.technology/news/fountain-life-named-exclusive-longevity-partner-of-houstonian-hotel-and-spa/__________Hosts:Phil Newman: ⁠https://qrco.de/bgXpNY⁠Nina Patrick: ⁠https://qrco.de/bgXpKn⁠

Guests:Nabiha SaklayenCEO and Co-Founder of CellinoLinkedIn: https://www.linkedin.com/in/nabihasaklayen/Cellino: https://cellinobio.com/Vladik KrupalnikCEO and Co-Founder of RenewalBioLinkedIn: https://www.linkedin.com/in/vladik-krupalnik-0669b729/RenewalBio: https://www.renewal.bio/________What can regenerative medicine teach us about health, longevity, and personalized medicine?Phil Newman and Dr. Nina Patrick sit down with biotech pioneers Nabiha Saklayen and Vladik Krupalnik to explore how cutting-edge stem cell technologies are transforming medicine. They discuss how induced pluripotent stem cells (iPSCs) can be scaled for various applications, from rare blood disorders to organ-specific cells, and how these approaches could redefine healthspan and lifespan.Beyond individual treatments, Nabiha and Vladik share their visions for decentralized, on-demand cell manufacturing, regulatory strategies, and AI-driven platforms that could make personalized regenerative medicine accessible globally. They also highlight how infrastructure, standardization, and investor alignment are shaping the trajectory of longevity-focused biotech.This conversation combines the science of regenerative medicine with practical insights for anyone interested in extending healthspan, optimizing personalized therapies, and leveraging technology to transform medicine. Subscribe for weekly episodes on longevity science, regenerative medicine, and the innovations shaping our future.In this episode, you’ll learn:How iPSCs are being used to generate blood, liver, heart, and pancreatic cellsStepwise strategies for moving from preclinical work to first-in-human trialsThe distinction between science fiction and realistic regenerative therapiesHow decentralized manufacturing can safely bring therapies closer to patientsInvestor perspectives on longevity and regenerative medicineHow personalized cell therapies may eventually extend human healthspanIf you care about living longer and healthier, and you’re curious about how regenerative medicine could redefine personalized healthcare, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan extension, and the breakthrough technologies shaping the future of regenerative and personalized medicine.__________Connect with our Hosts:Phil Newman: https://qrco.de/bgXpNY Dr. Nina Patrick: https://qrco.de/bgXpKn

Sponsor: The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.__________________News & References:Vector Y wins FDA Fast Track for ALS therapy → https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/FDA clears safety step for Loyal’s senior dog longevity drug → https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/Cumulus proves brain plasticity can be measured at scale → https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/50M boost secured for BioBeat’s wearable blood pressure tech → https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/Engitix raises $25M to target tissue aging at its source → https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/Corsera lands $80M to predict and prevent cardiovascular disease → https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/Proxima lands $80M to make protein interactions programmable → https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/__________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn

Guest: Lucas di Grassi Website: https://digrassi.com/Instagram: https://www.instagram.com/lucasdigrassi/Sponsor: The Longevity Show Website: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________________What can professional racing teach us about health, longevity, and peak human performance?Phil Newman and Dr. Nina Patrick sit down with Formula E and endurance racing champion Lucas di Grassi to explore how elite athletes optimize metabolism, nutrition, hydration, and supplementation to maintain health under extreme stress. Lucas shares his personal strategies, from microbiome-focused supplements and metabolic flexibility to controlling stress and tracking biological age.Beyond personal optimization, Lucas discusses emerging technologies that could revolutionize human healthspan, including AI-driven digital twins, protein design with AlphaFold 2, and continuous biometric monitoring. He also shares his insights on how lessons from motorsport telemetry, environmental awareness, and data-driven decision-making can translate to everyday life and longevity.This conversation combines the science of performance with practical insights for anyone seeking to improve healthspan, optimize lifestyle, and leverage technology to extend both lifespan and quality of life. Subscribe for weekly episodes on longevity science, health optimization, and the innovations shaping our future.Key Topics:Lessons from professional racing for metabolism, nutrition, and hydrationStress management and biological age trackingAI-driven digital twins and protein design with AlphaFold 2Continuous biometric monitoring and data-driven health insightsTranslating elite performance strategies to everyday longevityIf you care about living longer and healthier while optimizing your performance and lifestyle, this is a conversation you don’t want to miss.Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.__________Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem from validated lifestyle science and AI-driven drug discovery to breakthrough clinical trials, CES health tech, and the future of longevity investing.A new study in the International Journal of Epidemiology confirms that Blue Zone populations still enjoy statistically significant longevity advantages, highlighting the role of community, movement, and diet in healthy aging.Insilico Medicine made headlines with its Hong Kong IPO, raising $293M and signaling strong investor confidence in AI-driven longevity biotech. The company also secured an $888M oncology collaboration with Servier, marking a major step for AI-powered drug discovery.At CES, Withings unveiled its at-home Longevity Station, a device that measures 60 biomarkers in just 90 seconds. It tracks cardiovascular function, vascular health, cellular composition, and early cardiometabolic risk, bringing advanced health monitoring into the home.Retro Biosciences dosed the first patient in a phase one trial of its autophagy-targeting drug, RTR242, a key milestone for clinical-stage longevity therapeutics.Human clinical evidence from El Nutra’s ProLon fasting-mimicking diet demonstrates measurable activation of autophagy, supporting cellular renewal, improved insulin sensitivity, and metabolic health.----------News & References:Insilico debuts on HK stock exchange, locking in more than $290M → https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/Insilico Medicine and Servier agree up to US$888M oncology collaboration → https://longevity.technology/news/insilico-medicine-and-servier-agree-up-to-us888-m-oncology-drug-discovery-collaboration/Retro Bio commences first-in-human trial for RIP242 → https://longevity.technology/news/retro-bio-commences-first-in-human-trial/Why long-bio is poised for a breakout at JPM 2026 → https://longevity.technology/news/why-longbio-is-poised-for-a-breakout-at-jpm-2026/Withings launches at-home Longevity Station at CES → https://longevity.technology/news/withings-launches-at-home-longevity-station-at-ces/First human trial links fasting-mimicking diet to cellular renewal → https://longevity.technology/news/first-human-trial-links-fasting-mimicking-diet-to-cellular-renewal/New study reaffirms Blue Zones longevity claims → https://longevity.technology/news/new-study-reaffirms-blue-zones-longevity-claims/----------Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

GLP-1 drugs have exploded into the mainstream, but are they truly longevity medicines, or simply powerful tools for treating obesity and metabolic disease?In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit down with two of the world’s leading authorities to unpack one of the most important health debates of our time: Should we all be taking GLP-1 agonists?Joining the conversation are Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Professor Jens Juul Holst, the scientist who first discovered the GLP-1 hormone. Together, they explore the science, hype, risks, and real-world implications of drugs like Ozempic, Wegovy, and tirzepatide going far beyond weight loss headlines.From insulin resistance and inflammation to cardiovascular protection, brain health, and the future of preventive medicine, this wide-ranging discussion examines whether GLP-1s could redefine how we think about aging itself. The episode also tackles difficult questions around microdosing, off-label use, muscle loss, access, regulation, and the ethics of medicating lifestyle versus disease.Key Topics: What GLP-1 agonists actually do in the bodyObesity, metabolic syndrome, and lifespanWeight-independent longevity effectsInflammation, cardiovascular and renal protectionBrain health and Alzheimer’s diseaseMicrodosing, personalization, and patient-led experimentationRisks, side effects, and media exaggerationAre GLP-1s the first true preventive longevity drugs?If you care about living longer and healthier and understanding the trade-offs along the way, this is a conversation you don’t want to miss.Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.----------Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

Longevity.Technology UNLOCKED is here!Phil Newman and Dr. Nina Patrick are launching a brand-new series exploring the ideas, science, and stories shaping how we live longer, healthier lives.First episode drops January 5th: GLP-1s – Should We All Be Taking Them? with Dr. Jens Juul Holst and Dr. Eric Verdin. Expect real science, clear answers, and practical takeaways you can actually use.Why subscribe now?Be the first to hear every episodeGet insights from leading experts before they hit the headlinesLearn actionable tips to optimize your healthspanJoin a curious, longevity-minded community#LongevityUnlocked #LongevityPodcast #FutureOfHealth #GLP1 #LongevityTechnology